2483-65-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-pyrrolidin-2-one is used as a key intermediate in the development of drugs for the treatment of various central nervous system disorders. Its unique structure and properties allow for the creation of novel therapeutic agents that can target specific neurological conditions.
Used in Organic Synthesis:
3-Amino-pyrrolidin-2-one serves as a valuable building block in the synthesis of other organic compounds. Its reactivity and functional groups enable the formation of a wide range of chemical products, contributing to the advancement of organic chemistry.
Used in Chemistry and Material Science:
3-Amino-pyrrolidin-2-one has potential applications as a building block for the creation of new materials in the fields of chemistry and material science. Its unique structure and properties can be utilized to develop innovative materials with specific characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C4H8N2O/c5-3-1-2-6-4(3)7/h3H,1-2,5H2,(H,6,7)

Upstream product

• 1003-51-6 3-amino-1-hydroxypyrrolidin-2-one 
• 37529-96-7 methyl ester of 2,4-diaminobutyric acid 
• 6970-28-1 DL-2,4-diaminobutyric acid dihydrochloride 
• 49846-91-5 methyl 4,5-dihydro-1H-pyrazole-3-carboxylate 
• 305-62-4 2,4-diaminobutanoic acid 

Downstream Products

• 305-62-4 2,4-diaminobutanoic acid 
• 1208005-10-0 3-[{1[bis(4-Chlorophenyl)methyl]azetidin-3-yl}(methyl-sulphonyl)amino]-5-fluoro-N-(2-oxopyrrolidin-3-yl)benzamide 
• 99780-97-9 (2-oxo-pyrrolidin-3-(S)-yl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

ACC INHIBITORS AND USES THEREOF

The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

Catalytic hydrogenation of methyl esters of some 1H-pyrazoline-3-carboxylic acids

Hydrogenation over Raney nickel of the methyl ester of 1H-pyrazoline-3- carboxylic acid and also of its 4-phenyl and 5-methoxycarbonyl-substituted analogs, leads respectively to 3-aminopyrrolidin-2-one, its 4-phenyl- and 5-methoxycarbonyl derivatives, pre

Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position

Pyrrolidine(thi)one compounds substituted by heterocyclic substituents in the 3-position, their preparation and use in pharmaceutical compositions, in particular as immunomodulators for treatment and/or inhibition of inflammatory and autoimmune diseases and haematological-oncological diseases.

N-type calcium channel blockers

The invention relates to novel 3-amino pyrrolidine derivatives, as well as methods for modulating calcium channel activity and for treating conditions associated with calcium channel function. In particular, the compounds generally contain at least one be

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

There are described according to the invention compounds of formula (I) (relative stereochemistry indicated), wherein R1, R2, R3 and X are as defined in the specification, together with processes for preparing them, compositions containing them and their use as pharmaceuticals. Compounds of formula (I) are indicated inter alia for the treatment of chronic bronchitis.

A flexible, practical, and stereoselective synthesis of enantiomerically pure trans-5-oxohexahydropyrrolo[3,2-b]pyrroles (pyrrolidine-trans-lactams), a new class of serine protease inhibitors, using acyliminium methodology

A flexible, practical, and stereoselective synthesis of enantiomerically pure trans-5-oxohexahydropyrrolo[3,2-b]pyrroles (pyrrolidine-trans-lactams) is described. The key reaction involves addition of Z-ketene acetal 24 to the acyliminium ion derived from 48. This reaction is mediated by BF3. OEt2 and introduces the 6S and 6aS stereocenters stereoselectively. The acyliminium precursor was prepared in four different ways: from racemic 2,4- diaminobutyric acid 8, from (R)-asparagine, from (R)-methionine, and via a crystallization-induced dynamic resolution of a salt of the racemic amine 56. (R)-Methionine is the preferred starting material for the preparation of enantiomerically pure material. The best conditions for addition of the ketene acetal to the acyliminium ion derived from 48 were determined by systematically screening a range of ketene acetals and Lewis acids. The best ketene acetal was Z-(1-ethoxy-3-methylbut-1-enyloxyl)triisopropylsilane 24. In this series, the bulk of the silyl group of the Z-ketene acetal can be correlated with increased 6S isopropyl product. Use of the E-ketene acetal does not lead to a significant change in stereoselectivity for the 6R isopropyl product. In contrast, variation of the Lewis acid has a considerable effect on the product stereochemistry. While BF3·OEt2 gives predominantly 6S,6aS product, AlCl3 and TiCl4 give predominantly mixtures of the 6R,6aS and 6S,6aS products and TMSOTf gives 6aR material with predominantly one unknown isopropy] isomer (trans-lactam numberings used). The synthesis can conveniently be carried out on a large scale to produce multigram quantities of the trans-lactam 28, which is a key precursor of pharmacologically active molecules such as 1, a selective and orally active human neutrophil elastase inhibitor. The overall chemical yield of 1 is 1.3%, corresponding to an average of >70% yield for each of the 14 steps, and the synthesis contains only one chromatographic purification.

Competitive intramolecular aminolysis: Relative rates of 5-and 6-membered lactam ring closure

Methyl 4,5-diaminopentanoate (4,5-Dape Me) undergoes competitive intramolecular aminolysis to 5-aminomethyl-2-pyrrolidinone (L5) and 5-amino-2-piperidinone (L6) in dilute alkaline aqueous solution at 25°C. Use of this single compound provides an ideal case for assessing the relative rates of 5- and 6-membered lactam ring closure. Assessments are also made using the intramolecular aminolysis of pairs of compounds: methyl 2,4-diaminobutanoate (2,4-Dab Me) and methyl 2,5-diaminopentanoate (2,5-Dape Me); methyl 4-aminobutanoate (4-Ab Me) and methyl 5-aminopentanoate (5-Ape Me).